Organization: Deep Genomics

Opinion Leader: Canada’s early focus on artificial intelligence is starting to reap commercial benefits

Canada’s early contributions and long-standing academic expertise in artificial intelligence are now generating growing funding for and revenue in AI in drug development, but the country’s AI-enabled drug development industry faces significant challenges in coming years, Dr. Ulrik Kristensen, PhD, founder and principal analyst at UK-based Emersion Insights, says in an op-ed.